Showing 41 - 50 of 509
The application of Bayesian statistical analyses has been facilitated in recent years by methodological advances and an increasing complexity necessitated within research. Substantial debate has historically accompanied this analytic approach relative to the frequentist method, which is the...
Persistent link: https://www.econbiz.de/10005404905
The literature reporting economic evaluations related to the treatment of Alzheimer's disease (AD) has developed over the last decade. Most analyses have used economic models to estimate the cost effectiveness of drugs for the treatment of AD. This review considers the range of methods used in...
Persistent link: https://www.econbiz.de/10005404907
DOI: 10.2165/0019053-200826090-00003
Persistent link: https://www.econbiz.de/10005404908
Persistent link: https://www.econbiz.de/10005404912
Persistent link: https://www.econbiz.de/10005404922
Persistent link: https://www.econbiz.de/10005404930
A comprehensive, multinational literature search was conducted of all articles published from 1993 to 2003 regarding the cost effectiveness of antidepressant drugs, with special emphasis on comparing third-generation antidepressants (TGAs) with tricyclic antidepressants (TCAs) and selective...
Persistent link: https://www.econbiz.de/10005404934
In recent years, several countries have experienced increases in the incidence of serogroup C meningococcal disease. It can be controlled with older polysaccharide vaccines and particularly the recently developed conjugate vaccines. For 21 developed countries, we investigated the role that...
Persistent link: https://www.econbiz.de/10005404941
To support decision making, many countries have now introduced some formal assessment process to evaluate whether health technologies represent good `value for money'. These often take the form of decision models that can be used to explore elements of importance to generalisability of study...
Persistent link: https://www.econbiz.de/10005404948
The broad availability of genetic information and technologies heralds an era when practitioners will utilise genomic testing to individualise patients Assessing the incremental cost effectiveness of a pharmacogenomic strategy involves examination of factors associated with the genotype of...
Persistent link: https://www.econbiz.de/10005404955